{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:12:27Z","timestamp":1793211147812,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic rhinosinusitis with nasal polyps (CRSwNP) affects up to 4.5% of the population and is frequently driven by type 2 inflammation. Dupilumab, targeting IL\u20114 and IL\u201113 pathways, was approved in 2019 as the first biologic for CRSwNP in Germany. This single-center, retrospective study analyzed 174 patients initiating dupilumab between 2019 and 2023. Patients were grouped by year and assessed for trends in demographics, surgical history, and treatment response. Only adherent patients with \u2265\u20096 months of follow-up were included. Age and baseline disease severity were stable across cohorts. However, the proportion of patients with &gt;\u20093 prior sinus surgeries declined from 28.3% in 2019\/20 to 13.0% in 2023, suggesting earlier biologic initiation over time. All patients met at least three EPOS 2020 criteria. Significant and clinically meaningful improvements were observed in all cohorts for Nasal Polyp Score (NPS), SNOT\u201122, VAS, and olfactory testing, with changes exceeding established minimal clinically important differences (MCIDs). No cohort showed superior outcomes. Tese findings highlight consistent real-world efficacy of dupilumab and evolving prescribing patterns that favor earlier intervention, while reflecting continued cautious patient selection in the context of high treatment costs.<\/jats:p>","DOI":"10.1038\/s41598-025-17787-4","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:53:50Z","timestamp":1766080430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evolving trends in dupilumab use for chronic rhinosinusitis with nasal polyps (CRSwNP): a 4-year cohort analysis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-9999","authenticated-orcid":false,"given":"Patrick","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Gr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Stihl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Frankenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Gellrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"3","key":"17787_CR1","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw, T. M. et al. Chronic rhinosinusitis with nasal polyps and asthma. J. Allergy Clin. Immunol. Pract. 9 (3), 1133\u20131141 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"17787_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/JAA.S290424","volume":"14","author":"C Bachert","year":"2021","unstructured":"Bachert, C. et al. Burden of disease in chronic rhinosinusitis with nasal polyps. J. Asthma Allergy. 14, 127\u2013134 (2021).","journal-title":"J. Asthma Allergy"},{"issue":"Suppl S29","key":"17787_CR3","first-page":"1","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens, W. J. et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58 (Suppl S29), 1\u2013464 (2020).","journal-title":"Rhinology"},{"issue":"4","key":"17787_CR4","first-page":"421","volume":"62","author":"J Mullol","year":"2024","unstructured":"Mullol, J. et al. Prevalence of chronic rhinosinusitis without\/with nasal polyps according to severity in Spain. Rhinology 62 (4), 421\u2013431 (2024).","journal-title":"Rhinology"},{"issue":"9","key":"17787_CR5","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1111\/all.15301","volume":"77","author":"A Starry","year":"2022","unstructured":"Starry, A. et al. Epidemiology and treatment of patients with chronic rhinosinusitis with nasal polyps in Germany-A claims data study. Allergy 77 (9), 2725\u20132736 (2022).","journal-title":"Allergy"},{"issue":"4","key":"17787_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","volume":"4","author":"WW Stevens","year":"2016","unstructured":"Stevens, W. W., Schleimer, R. P. & Kern, R. C. Chronic rhinosinusitis with nasal polyps. J. Allergy Clin. Immunol. Pract. 4 (4), 565\u2013572 (2016).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"17787_CR7","doi-asserted-by":"crossref","unstructured":"De Corso, E. et al. Sinonasal biomarkers defining type 2-High and type 2-Low inflammation in chronic rhinosinusitis with nasal polyps. J. Pers. Med. 12(8), 1251 (2022).","DOI":"10.3390\/jpm12081251"},{"issue":"1","key":"17787_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","volume":"147","author":"C Bachert","year":"2021","unstructured":"Bachert, C. et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J. Allergy Clin. Immunol. 147 (1), 29\u201336 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"17787_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/5584_2021_640","volume":"1347","author":"M Folci","year":"2021","unstructured":"Folci, M. et al. Eosinophils as major player in type 2 inflammation: autoimmunity and beyond. Adv. Exp. Med. Biol. 1347, 197\u2013219 (2021).","journal-title":"Adv. Exp. Med. Biol."},{"key":"17787_CR10","unstructured":"GmbH, S. A. D. Dupixent 300\u00a0mg Injektionsl\u00f6sung im Fertigpen\/-in einer Fertigspritze.  https:\/\/www.rote-liste.de\/suche\/praep\/26905\/Dupixent%20300%20mg%20Injektionsl%C3%B6sung%20in%20einer%20Fertigspritze%20%20Fertigspritzen%20mit%20automatischem%20Sicherheitssystem. Accessed 17 Aug 2023 (2023)."},{"issue":"6","key":"17787_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s15007-022-5080-1","volume":"31","author":"L Klimek","year":"2022","unstructured":"Klimek, L. et al. Dokumentation von Biologika-Therapien Bei chronischer rhinosinusitis Mit polyposis Nasi (CRSwNP): Dupilumab, Omalizumab und mepolizumab: Empfehlungen des \u00e4rzteverbandes Deutscher allergologen (AeDA) und der Deutschen gesellschaft f\u00fcr HNO-Heilkunde, Kopf- und halschirurgie (DGHNOKHC). Allergo J. 31(6), 24\u201339 (2022).","journal-title":"Allergo J."},{"key":"17787_CR12","doi-asserted-by":"crossref","unstructured":"Harb, H. & Chatila, T. A. Mechanisms Dupilumab. Clin. Exp. Allergy, 50(1), 5\u201314 (2020).","DOI":"10.1111\/cea.13491"},{"issue":"2","key":"17787_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/all.15134","volume":"77","author":"RJL van der Lans","year":"2022","unstructured":"van der Lans, R. J. L. et al. Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy 77 (2), 670\u2013674 (2022).","journal-title":"Allergy"},{"issue":"10","key":"17787_CR14","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1111\/all.15772","volume":"78","author":"E De Corso","year":"2023","unstructured":"De Corso, E. et al. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational phase IV real-life study (DUPIREAL). Allergy 78 (10), 2669\u20132683 (2023).","journal-title":"Allergy"},{"key":"17787_CR15","doi-asserted-by":"crossref","unstructured":"Huber, P. et al. Real-world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years. Allergy 79(11), 3108\u20133117 (2024).","DOI":"10.1111\/all.16263"},{"issue":"9","key":"17787_CR16","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","volume":"22","author":"P Kolkhir","year":"2023","unstructured":"Kolkhir, P. et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat. Rev. Drug Discov. 22 (9), 743\u2013767 (2023).","journal-title":"Nat. Rev. Drug Discov"},{"issue":"6","key":"17787_CR17","doi-asserted-by":"publisher","first-page":"e12376","DOI":"10.1002\/clt2.12376","volume":"14","author":"T Mora","year":"2024","unstructured":"Mora, T. et al. Prevalence and coexistence of type 2 inflammatory diseases. Clin. Transl Allergy. 14 (6), e12376 (2024).","journal-title":"Clin. Transl Allergy"},{"issue":"3","key":"17787_CR18","first-page":"213","volume":"58","author":"ES Lourijsen","year":"2020","unstructured":"Lourijsen, E. S., Fokkens, W. J. & Reitsma, S. Direct and indirect costs of adult patients with chronic rhinosinusitis with nasal polyps. Rhinology 58 (3), 213\u2013217 (2020).","journal-title":"Rhinology"},{"issue":"3 Pt 2","key":"17787_CR19","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S0194-5998(97)70005-6","volume":"117","author":"VJ Lund","year":"1997","unstructured":"Lund, V. J. & Kennedy, D. W. Staging for rhinosinusitis. Otolaryngol. Head Neck Surg. 117 (3 Pt 2), S35\u201340 (1997).","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"4","key":"17787_CR20","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/all.15650","volume":"78","author":"P Gevaert","year":"2023","unstructured":"Gevaert, P. et al. European academy of allergy and clinical immunology position paper on endoscopic scoring of nasal polyposis. Allergy 78 (4), 912\u2013922 (2023).","journal-title":"Allergy"},{"issue":"5","key":"17787_CR21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.jaci.2010.02.020","volume":"125","author":"T Van Zele","year":"2010","unstructured":"Van Zele, T. et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J. Allergy Clin. Immunol. 125 (5), 1069\u20131076e4 (2010).","journal-title":"J. Allergy Clin. Immunol."},{"key":"17787_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.parkreldis.2016.09.023","volume":"33","author":"M Lawton","year":"2016","unstructured":"Lawton, M. et al. Equating scores of the university of Pennsylvania smell identification test and sniffin\u2019 sticks test in patients with Parkinson\u2019s disease. Parkinsonism Relat. Disord. 33, 96\u2013101 (2016).","journal-title":"Parkinsonism Relat. Disord"},{"issue":"3","key":"17787_CR23","first-page":"194","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens, W. J. et al. EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology 61 (3), 194\u2013202 (2023).","journal-title":"Rhinology"},{"issue":"10209","key":"17787_CR24","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert, C. et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394 (10209), 1638\u20131650 (2019).","journal-title":"Lancet"},{"key":"17787_CR25","doi-asserted-by":"crossref","unstructured":"De Corso, E. et al. Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: A real-life observational study in the first year of treatment. J. Clin. Med. 11(10) (2022).","DOI":"10.3390\/jcm11102684"},{"issue":"6","key":"17787_CR26","first-page":"435","volume":"60","author":"BR Haxel","year":"2022","unstructured":"Haxel, B. R. et al. Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps. Rhinology 60 (6), 435\u2013443 (2022).","journal-title":"Rhinology"},{"issue":"5","key":"17787_CR27","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.waojou.2023.100780","volume":"16","author":"T Albrecht","year":"2023","unstructured":"Albrecht, T. et al. Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy. World Allergy Organ. J. 16 (5), 100780 (2023).","journal-title":"World Allergy Organ. J."},{"issue":"3","key":"17787_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/alr.23483","volume":"15","author":"C Dorismond","year":"2025","unstructured":"Dorismond, C. et al. Real-world predictors of dupilumab prescription in patients with chronic rhinosinusitis with nasal polyps. Int. Forum Allergy Rhinol. 15 (3), 278\u2013286 (2025).","journal-title":"Int. Forum Allergy Rhinol"},{"issue":"10","key":"17787_CR29","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.jaip.2023.07.038","volume":"11","author":"IL Schmale","year":"2023","unstructured":"Schmale, I. L. et al. Chronic rhinosinusitis with nasal polyposis treated with dupilumab: Real-world use and outcomes. J. Allergy Clin. Immunol. Pract. 11 (10), 3203\u20133210 (2023).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"17787_CR30","unstructured":"Bundesausschuss, G. Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Dupilumab (Dupixent\u00ae) (webpage). Accessed 04 Nov 2024 (2024)."},{"issue":"6","key":"17787_CR31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/alr.22936","volume":"12","author":"AK Parasher","year":"2022","unstructured":"Parasher, A. K. et al. Economic evaluation of dupilumab versus endoscopic sinus surgery for the treatment of chronic rhinosinusitis with nasal polyps. Int. Forum Allergy Rhinol. 12 (6), 813\u2013820 (2022).","journal-title":"Int. Forum Allergy Rhinol"},{"issue":"1","key":"17787_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13223-023-00823-1","volume":"19","author":"M Yong","year":"2023","unstructured":"Yong, M. et al. Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada. Allergy Asthma Clin. Immunol. 19 (1), 90 (2023).","journal-title":"Allergy Asthma Clin. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17787-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17787-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17787-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T01:02:37Z","timestamp":1766538157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17787-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17787"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17787-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"15 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44338"}}